Pipeline

Preclinical Programs

Agios has led the field of cancer metabolism with its novel IDH and MTAP programs and continues to make important advances in the field of rare genetic diseases with its PKR program. These programs exemplify our strategy of applying our foundational expertise in cellular metabolism and precision medicine to translated science from our labs into first-of-their-kind experimental therapies. In addition to advancing our lead programs, we continue to discover novel metabolic targets that meet a high bar for future development across all three of our core focus areas: cancer metabolism, rare genetic diseases and metabolic immuno-oncology.